Centre for Doctoral Training in Transformative Pharmaceutical Technologies 14692dtp-960

The CDT is a partnership between the University of Nottingham, University College London (UCL), and the Synthesis & Solid State Pharmaceutical Centre (SSPC) in Ireland. It builds on our highly successful previous CDTs in Targeted Therapeutics and Advanced Therapeutics & Nanomedicines.

Funded by the Engineering and Physical Sciences Council, Science Foundation Ireland and a total of 19 industry partners, we provide world-leading training to prepare inspired and strategic-thinking scientists ready for high achieving careers in the pharmaceutical and healthcare sectors. Students on the CDT develop exceptionally high-level scientific skills through a cutting-edge PhD research project, in addition to honing their transferrable, innovation and critical skills via mini-projects and an integrated university-industry training programme.

Applications for 2020

Applications for our first round of recruitment have now ended. However, we will continue to accept applications until all places are filled. Please check back here for further updates. 


About the Centre

coloured test tubes290x94

Our aims, partnerships and training programmes



What you can expect to receive from our PhD studenships

PhD studentships


Find out about our studentships, funding and how to apply



Our partners

orange and pink tablets290x94

Meet the partners involved with our Centre for Doctoral Training

The team

test tubes and man-290x94

Get in touch with us

Find us on twitter


What are transformative pharmaceutical technologies?

A drug is a molecule that acts upon biological processes in the body. In contrast, a medicine is a complex product that comprises the drug and other ingredients packaged into a final dosage form that can be administered to a patient to ensure there is a beneficial therapeutic effect with minimum side-effects.

To achieve therapeutic effect it is essential to ensure that the drug is delivered to the appropriate site in the body, at the right time, and in the correct amount. This is challenging: some drug molecules are poorly soluble in biological milieu, while others are either not stable or have toxic side-effects and require careful processing into medicines to ensure they remain biologically active and safe.

The new drug molecules arising from drug discovery and biotechnology have particularly challenging properties. Pharmaceutical technologies are central to developing medicines from these molecules, to ensure patients are provided with safe and efficacious therapy.